2,2,2-trifluoro-N-(2-methyl-1-oxo-indan-2-yl)-acetamide | 312753-92-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2,2,2-trifluoro-N-(2-methyl-1-oxo-indan-2-yl)-acetamide
• 英文别名: 2,2,2-trifluoro-N-(2-methyl-3-oxo-1H-inden-2-yl)acetamide
• CAS: 312753-92-7
• 化学式: C₁₂H₁₀F₃NO₂
• 分子量: 257.212
• InChiKey: TZZBVFJJRUDHNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,2,2-trifluoro-N-(2-methyl-1-oxo-indan-2-yl)-acetamide 在 aluminum (III) chloride 、 lithium aluminium tetrahydride 、 硫酸 、 10% Pd/C 、 氢气 、 溶剂黄146 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 硝基甲烷 、 乙醇 、 二氯甲烷 、 水 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 189.0h， 生成 5,6-diethyl-2-methyl-indan-2-ylamine
  参考文献：
  名称：

  An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol

  摘要：

  The synthesis of a series of indacaterol analogues in which each of the three structural regions of indacaterol are modified in a systematic manner is described. Evaluation of the affinity of these analogues for the beta(2)-adrenoceptor identified the 3,4-dihydroquinolinone and 5-n-butylindanyl analogues to demonstrate the most similar profiles to indacaterol. An alpha-methyl aminoindane analogue was discovered to be 25-fold more potent than indacaterol, and functional studies revealed an atypical beta(2)-adrenoceptor activation profile for this compound consistent with that of a slowly dissociating 'super agonist'. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.096
• 作为产物：
  描述：

  2-甲基茚满-1-酮 在 氨 、 potassium hexacyanoferrate(III) 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 28.0h， 生成 2,2,2-trifluoro-N-(2-methyl-1-oxo-indan-2-yl)-acetamide
  参考文献：
  名称：

  An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol

  摘要：

  The synthesis of a series of indacaterol analogues in which each of the three structural regions of indacaterol are modified in a systematic manner is described. Evaluation of the affinity of these analogues for the beta(2)-adrenoceptor identified the 3,4-dihydroquinolinone and 5-n-butylindanyl analogues to demonstrate the most similar profiles to indacaterol. An alpha-methyl aminoindane analogue was discovered to be 25-fold more potent than indacaterol, and functional studies revealed an atypical beta(2)-adrenoceptor activation profile for this compound consistent with that of a slowly dissociating 'super agonist'. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.096

文献信息

• Beta2-adrenoceptor agonists
  申请人：Cuenoud Bernard

  公开号：US06878721B1

  公开（公告）日：2005-04-12

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  公式中的化合物以自由形式、盐或溶剂形式存在，其中Ar是化学式的一组，Y是碳或氮，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r如规范中所定义，它们的制备及其作为药物的用途，特别是用于治疗阻塞性或炎症性气道疾病。
• [EN] BETA2-ADRENOCEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR BETA 2-ADRENERGIQUE
  申请人：NOVARTIS AG

  公开号：WO2000075114A1

  公开（公告）日：2000-12-14

  Compounds of formula (I) in free or salt or solvate form, where Ar is a group of formula (II) Y is carbon or nitrogen and R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10¿, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. The compounds of formula (I) in free, salt or solvate form, have β2-adrenoreceptor agonist activity.

  公式（I）的化合物，其自由形式、盐形式或溶剂化合物形式中，其中Ar是公式（II）的基团，Y是碳或氮，R?1，R2，R3，R4，R5，R6，R7，R8，R9，R10，X，n，p，q和r如规范所定义，它们的制备以及它们作为药物的用途，特别是用于治疗阻塞性或炎性呼吸道疾病。公式（I）的化合物在自由、盐或溶剂化合物形式中具有β2-肾上腺素受体激动剂活性。
• BETA-2-ADRENORECEPTOR AGONISTS
  申请人：Cuenoud Bernard

  公开号：US20100029705A1

  公开（公告）日：2010-02-04

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  该化合物的化学式为自由或盐或溶剂形式，其中Ar是化学式的一组，Y是碳或氮，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义在说明书中，其制备以及其作为药物的用途，特别是用于治疗阻塞性或炎症性呼吸道疾病。
• β2-adrenoceptor agonists
  申请人：Novartis AG

  公开号：US07622483B2

  公开（公告）日：2009-11-24

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  公式为自由或盐或溶剂化合物，其中Ar是公式的一组，Y为碳或氮，而R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r如规范中所定义，其制备和用途作为药物，特别是用于治疗阻塞性或炎症性呼吸道疾病。
• Beta-2-adrenoreceptor agonists
  申请人：Novartis AG

  公开号：US08067437B2

  公开（公告）日：2011-11-29

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  该化合物的分子式为自由或盐或溶剂形式，其中Ar是公式的一组，Y是碳或氮，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义如规范所述，其制备和用途作为药物，特别是用于治疗阻塞性或炎症性呼吸道疾病。